Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Alexza Pharmaceuticals has an F-score of 4 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for Alexza Pharmaceuticals's Piotroski F-Score or its related term are showing as below:
Alexza Pharmaceuticals Piotroski F-Score Historical Data
The historical data trend for Alexza Pharmaceuticals's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Alexza Pharmaceuticals's current Net Income (TTM) was -24.27.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Alexza Pharmaceuticals's current Cash Flow from Operations (TTM) was -23.40.
==> Negative ==> Score 0.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
Alexza Pharmaceuticals's return on assets of this year was -0.56214964. Alexza Pharmaceuticals's return on assets of last year was -0.30925384.
==> Last year is higher ==> Score 0.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Alexza Pharmaceuticals's gearing of this year was 0.78530537. Alexza Pharmaceuticals's gearing of last year was 0.96555388.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Alexza Pharmaceuticals's current ratio of this year was 0.12332648. Alexza Pharmaceuticals's current ratio of last year was 3.30785099.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Alexza Pharmaceuticals's number of shares in issue this year was 20.807. Alexza Pharmaceuticals's number of shares in issue last year was 19.75.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Alexza Pharmaceuticals's gross margin of this year was -2.15949216. Alexza Pharmaceuticals's gross margin of last year was -3.45878049.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Alexza Pharmaceuticals's asset turnover of this year was 0.11677091. Alexza Pharmaceuticals's asset turnover of last year was 0.04802624.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
0
+
0
+
1
+
1
+
0
+
0
+
1
+
1
=
4
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Alexza Pharmaceuticals has an F-score of 4 indicating the company's financial situation is typical for a stable company.
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Alexza Pharmaceuticals Piotroski F-Score Related Terms
Thank you for viewing the detailed overview of Alexza Pharmaceuticals's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.
Alexza Pharmaceuticals (Alexza Pharmaceuticals) Business Description
Alexza Pharmaceuticals Inc was incorporated in the state of Delaware on December 19, 2000 as FaxMed, Inc. In June 2001, it changed the name to Alexza Corporation and in December 2001 it became Alexza Molecular Delivery Corporation. In July 2005, it changed the name to Alexza Pharmaceuticals, Inc. It is a pharmaceutical company, engaged in the research, development and commercialization of novel proprietary products for the acute treatment of central nervous system conditions. ADASUVE is its only approved product & there is one product candidate in active development, AZ-002 (Staccato alprazolam), which is being developed for the treatment of acute repetitive seizures, sometimes called cluster seizures or ARS. ADASUVE, or Staccato loxapine, and its product candidates are based on its proprietary technology, the Staccato system. The Staccato system vaporizes an excipient-free drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery. Because of the particle size of the aerosol, the drug is quickly absorbed through the deep lung into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous, or IV, administration but with greater ease, patient comfort and convenience. The pharmaceutical and biotechnology industries are intensely competitive. Many pharmaceutical companies, biotechnology companies, public and private universities, government agencies and research organizations are actively engaged in research and development of products targeting the same markets as ADASUVE and its other product candidates. The names "Alexza Pharmaceuticals," "Alexza," "Staccato" and "ADASUVE" are trademarks of the Company. It helds 195 issued and allowed U.S. and international patents. The testing, manufacturing, labeling, advertising, promotion, distribution, export and marketing of the Company's product candidates are subject to extensive regulation by governmental authorities in the United States and other countries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALXA has been successfully added to your 